Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Bullboard Posts
Comment by Riverfolkon May 06, 2020 1:05pm
78 Views
Post# 30993732

RE:Health Canada Approval

RE:Health Canada ApprovalAwareness will definitely grow if Health Canada does not object to a phase 2 trial. What was highlighted to me from the last news release was the Trial will test inflammation in the Lung and Kidney. As a long term shareholder, to me this is derisking the trial and makes me a lot more bullish. Now Arch could have 2 pathways to potential billion dollar markets with one trial! With Covid 19, the technology has potential to substantially reduce hospitalization and without Covid 19 we could see $22 a share annually. This isn't a recycled drug, this isn't an idea, this is a Patented Drug Library with no competition.

As for Halting, I have been in this play for 3 years and I have only see it halt once. Through FDA applications for phase 1, approvals etc. I would rather a End day or Before Market press release to and let the market do its thing.

Awareness is what I have found to be the underlying reason for lower volume this week and National Media could cover this story which would change the game forever.

Good luck to all longs 

I am invested in the science 
Bullboard Posts